• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Aerin Medical touts study of nasal airway obstruction treatment

Aerin Medical touts study of nasal airway obstruction treatment

July 13, 2021 By Sean Whooley

Aerin Medical VivAer
[Image from Aerin Medical]
Aerin Medical today touted results from a three-month study of its VivAer treatment for nasal airway obstruction (NAO).

Sunnyvale, Calif.-based Aerin’s VivAer was studied in the VATRAC trial, with results published by the International Forum of Allergy and Rhinology.

According to a news release, the study confirmed the safety and efficacy of VivAer in treating NAO caused by nasal valve collapse (NVC). Those treated with VivAer showed significant improvement in nasal obstruction symptoms compared to the control group.

The multi-center, prospective, single-blinded, randomized, sham-controlled trial enrolled 117 patients with extreme or severe NAO with NVC as a primary or significant contributor to their symptoms. Patients were randomized to undergo in-office treatment with VivAer or an in-office sham procedure that replicated the treatment experience without delivery therapeutic radiofrequency energy.

VATRAC met its primary and secondary endpoints, as treated patients demonstrated a significantly superior response rate with 88.3% of the treatment group registering at least a 20% improvement in NOSE (Nasal Obstruction Symptom Evaluation) score against 42.5% in the control. Symptom reduction came in at 55.1% improvement in mean NOSE score versus 21.3% in the control.

Treated patients saw significant improvements in nasal congestion, nasal blockage, breathing and sleeping and breathing during exercise or exertion. Treatment was generally well-tolerated with no serious adverse events related to the procedure.

VivAer, which holds both CE mark and FDA 510(k) approval, uses patented, temperature-controlled radiofrequency energy through a thin, wand-like stylus attached to a console. The stylus is inserted via the nostril to gently remodel the nasal tissue and improve airflow. Aerin Medical was included in MassDevice’s list of hottest startups in 2020.

“We believe that one reason NVC is commonly overlooked is the scarcity of non-invasive treatment options as an alternative to surgical repair,” Aerin Medical founder & CMO Dr. Scott Wolf said in the release. “To date, more than 30,000 people have been treated with VivAer, and the strong VATRAC trial results reflect our commitment to building a robust body of clinical evidence to support the safety and effectiveness of this non-invasive device.”

Filed Under: Clinical Trials, Featured, Otolaryngology/Ear, Nose & Throat (ENT), Radiosurgery/Radiation therapy, Respiratory Tagged With: Aerin Medical

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy